Article

Discovery of novel quinoline papain-like protease inhibitors for COVID-19 through topology constrained molecular generative model

2024-09-09

Abstract excerpt

The rapid emergence of drug-resistant SARS-CoV-2 variants poses a persistent challenge to current antiviral strategies. Mutations in key viral targets, including RNA-dependent RNA polymerase (RdRp), main protease (3CL pro ), and papain-like protease (PL pro ), have been shown to markedly reduce the efficacy of approved therapeutics, highlighting the urgent need for next-generation antivirals capable of overcomin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62c564d2-a006-5517-b7ff-4d5aad9cedac
DOI: 10.1101/2024.09.07.611841

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of novel quinoline papain-like protease inhibitors for COVID-19 through topology constrained molecular generative modelDOI 10.1101/2024.09.07.611841Read

De Novo Design and Bioactivity Prediction of SARS-CoV-2 Main Protease Inhibitors Using ULMFitSemantic proximity Read

New Potential Drug Candidates Against SARS-CoV-2 Using Generative ModelSemantic proximity Read

Massive Virtual screening and evaluation of small molecule inhibitors of the Papain-like protease of SARS-CoV-2Semantic proximity Read

Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT studySemantic proximity Read

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read

Multi-reference poly-conformational computational methods for de-novo design, optimization, and repositioning of pharmaceutical compoundsSemantic proximity Read

AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2Semantic proximity Read

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease InhibitorsSemantic proximity Read

High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity Read

Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like proteaseSemantic proximity Read

Massive Virtual screening and evaluation of small molecule inhibitors of the Papain-like protease of SARS-CoV-2Semantic proximity Read

In Silico Elucidation of Potent Inhibitors and Rational Drug Design against SARS-CoV-2 Papain-like ProteaseSemantic proximity Read